[go: up one dir, main page]

WO2007034278A3 - Fused imidazole derivatives as c3a receptor antagonists - Google Patents

Fused imidazole derivatives as c3a receptor antagonists Download PDF

Info

Publication number
WO2007034278A3
WO2007034278A3 PCT/IB2006/002561 IB2006002561W WO2007034278A3 WO 2007034278 A3 WO2007034278 A3 WO 2007034278A3 IB 2006002561 W IB2006002561 W IB 2006002561W WO 2007034278 A3 WO2007034278 A3 WO 2007034278A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
imidazole derivatives
fused imidazole
treating
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/002561
Other languages
French (fr)
Other versions
WO2007034278A2 (en
Inventor
Michelle Marie Claffey
Steven Wayne Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of WO2007034278A2 publication Critical patent/WO2007034278A2/en
Publication of WO2007034278A3 publication Critical patent/WO2007034278A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Aryl substituted imidazo[4,5-c] pyridine compounds are provided. These compounds are useful in pharmaceutical compositions as C3a antagonists for treating a variety of medical conditions associated with the Complement cascade. Methods for treating such conditions are also provided.
PCT/IB2006/002561 2005-09-19 2006-09-18 Fused imidazole derivatives as c3a receptor antagonists Ceased WO2007034278A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71845105P 2005-09-19 2005-09-19
US60/718,451 2005-09-19

Publications (2)

Publication Number Publication Date
WO2007034278A2 WO2007034278A2 (en) 2007-03-29
WO2007034278A3 true WO2007034278A3 (en) 2007-05-18

Family

ID=37779396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002561 Ceased WO2007034278A2 (en) 2005-09-19 2006-09-18 Fused imidazole derivatives as c3a receptor antagonists

Country Status (1)

Country Link
WO (1) WO2007034278A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2485113C2 (en) * 2007-11-02 2013-06-20 Хатчисон Медифарма Энтерпрайзис Cytokine inhibitors

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022075B2 (en) * 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
CN101594909A (en) * 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 IRAK Modulators for Treatment of Inflammatory Disorders, Cell Proliferative Disorders, Immune Disorders
EP2184273A1 (en) 2008-11-05 2010-05-12 Bayer CropScience AG Halogen substituted compounds as pesticides
AU2011229423B2 (en) * 2010-03-18 2015-12-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-infective compounds
WO2011137587A1 (en) * 2010-05-06 2011-11-10 Hutchison Medipharma Limited Cytokine inhibitors
US10039802B2 (en) 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
EP2986594B1 (en) 2013-04-15 2017-05-17 E. I. du Pont de Nemours and Company Fungicidal amides
AU2016269839B2 (en) 2015-06-03 2021-07-08 The University Of Queensland Mobilizing agents and uses therefor
AU2019416589B2 (en) 2018-12-29 2023-04-06 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound intermediate, preparation method therefor and application thereof
CN115745848A (en) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 Processing and synthesizing process of aminoguanidine
WO2025166319A1 (en) 2024-02-02 2025-08-07 The Broad Institute, Inc. Complement cascade inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
EP1104762A1 (en) * 1998-08-03 2001-06-06 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazo 1,2a]azines as selective inhibotors of cox-2
WO2001057038A1 (en) * 2000-02-01 2001-08-09 Basf Aktiengesellschaft Heterocyclic compounds and their use as parp inhibitors
WO2003051890A1 (en) * 2001-12-14 2003-06-26 Aegera Therapeutics Inc. Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides
WO2004111060A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics Inc. IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE SULFOXIDES AND SULFONES
WO2004111061A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics Inc. ACYLATED AND NON-ACYLATED IMIDAZO[2,1-b]-1,3,4,-THIADIAZOLE-2-SULFONAMIDES, AND USES THEREOF

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1104762A1 (en) * 1998-08-03 2001-06-06 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazo 1,2a]azines as selective inhibotors of cox-2
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
WO2001057038A1 (en) * 2000-02-01 2001-08-09 Basf Aktiengesellschaft Heterocyclic compounds and their use as parp inhibitors
WO2003051890A1 (en) * 2001-12-14 2003-06-26 Aegera Therapeutics Inc. Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides
WO2004111060A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics Inc. IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE SULFOXIDES AND SULFONES
WO2004111061A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics Inc. ACYLATED AND NON-ACYLATED IMIDAZO[2,1-b]-1,3,4,-THIADIAZOLE-2-SULFONAMIDES, AND USES THEREOF

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2485113C2 (en) * 2007-11-02 2013-06-20 Хатчисон Медифарма Энтерпрайзис Cytokine inhibitors

Also Published As

Publication number Publication date
WO2007034278A2 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
WO2007034282A3 (en) Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
EA201000615A1 (en) IMIDAZO [1,2-A] PYRIDINE DERIVATIVES APPLICABLE AS APC INHIBITORS (ACTIVIN-like KINASE)
IL204693A0 (en) Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
MX2009012567A (en) 3-(imidazolyl)-pyrazolo[3,4-b]pyridines.
WO2007027734A3 (en) Bicyclic and bridged nitrogen heterocycles
ZA201000212B (en) Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treatment of inflammation
MX2009004715A (en) Heterocyclic compounds as antiinflammatory agents.
WO2007106469A3 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2006126081A3 (en) Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
GEP20135780B (en) Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
WO2008091670A3 (en) Organic semiconductor materials and precursors thereof
PL1904494T3 (en) Imidazo[1,2-a]pyridine compounds as vegf-r2 inhibitors
WO2009016564A3 (en) 2-aza-bicyclo[3.3.0]octane derivatives
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
WO2007073432A3 (en) Piperidine derivatives and methods of use
EP1814885A4 (en) Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
WO2009156951A3 (en) 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
WO2006059149A8 (en) Arylsulfonylnaphthalene derivatives as 5ht2a antagonists
WO2007034278A3 (en) Fused imidazole derivatives as c3a receptor antagonists
NZ552137A (en) New 4-benzylidene-piperidin derivatives
WO2007104485A3 (en) Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06808851

Country of ref document: EP

Kind code of ref document: A2